<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraoperative problems after cardiopulmonary bypass</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraoperative problems after cardiopulmonary bypass</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intraoperative problems after cardiopulmonary bypass</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael G Fitzsimons, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2808430897"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiovascular and other systemic perturbations are frequently encountered immediately after weaning from cardiopulmonary bypass (CPB). These are often predictable based upon patient-specific and cardiac surgical procedure-specific factors. However, some patients experience unpredictable, sudden, or severe complications that require immediate intervention and/or an urgent reinstitution of CPB. Patients successfully weaned from CPB may continue to have challenges during the early post-bypass period.</p><p>This topic will discuss intraoperative problems that are commonly encountered in the immediate postbypass period. A detailed discussion of management of bleeding and coagulopathy after CPB is available in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass"</a>.)</p><p>Patient management during CPB and the process of weaning from CPB support are described in separate topics. (See  <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass"</a> and  <a class="medical medical_review" href="/z/d/html/90614.html" rel="external">"Weaning from cardiopulmonary bypass"</a>.)</p><p>Problems in the immediate postoperative period are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/135261.html" rel="external">"Postoperative care after cardiac surgery"</a>.)</p><p class="headingAnchor" id="H3061741351"><span class="h1">CARDIOVASCULAR PROBLEMS</span></p><p class="headingAnchor" id="H3574681701"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Cardiovascular instability can occur immediately after cardiac surgical procedures requiring CPB, often with resultant hypotension [<a href="#rid1">1</a>]. In this setting, clinically significant hypotension is usually due to one or more of the following problems:</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate <strong>preload</strong>, which impairs filling of the left ventricle (LV)</p><p class="bulletIndent1"><span class="glyph">●</span>Compromised <strong>contractility</strong>, which may be due to either global or focal LV or right ventricle (RV) dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased <strong>afterload</strong>, which manifests as reduced systemic vascular resistance (SVR) and vasoplegia</p><p class="bulletIndent1"><span class="glyph">●</span>Too low or excessively high <strong>heart</strong> <strong>rate </strong>(HR)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhythm</strong> other than sinus rhythm, with loss of atrioventricular (AV) synchrony </p><p></p><p>Before initiating treatment of hypotension, it is important to determine whether a central to peripheral arterial pressure gradient accounts for the appearance of low blood pressure (BP) on the monitored arterial tracing  (<a class="graphic graphic_figure graphicRef111035" href="/z/d/graphic/111035.html" rel="external">figure 1</a>). These non-physiologic gradients commonly occur following CPB, and consequently, therapy targeted to treat a low radial artery pressure may be inappropriate. In one prospective study, the arterial pressure in the radial artery underestimated the femoral pressure in 34 percent of 435 patients, with a systolic BP difference ≥25 mmHg or a mean arterial pressure (MAP) difference ≥10 mmHg [<a href="#rid2">2</a>]. Such significant gradients were more likely in patients with smaller body surface area, longer aortic cross-clamping time, less fluid administration, or a preoperative history of hypertension.</p><p>A general guide to treatment of hypotension during and after weaning from CPB is described in the table  (<a class="graphic graphic_table graphicRef93595" href="/z/d/graphic/93595.html" rel="external">table 1</a>), and greater detail is provided below.</p><p class="headingAnchor" id="H270051511"><span class="h2">Left ventricular dysfunction</span><span class="headingEndMark"> — </span>LV dysfunction may occur due to preexisting chronic ventricular dysfunction, and may be exacerbated by myocardial ischemia, stunning, or ischemia/reperfusion injury occurring during CPB with cardioplegia-induced cardiac arrest. (See  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Cardiac dysfunction'</a>.)</p><p>Myocardial injury resulting in postbypass ischemia or infarction is particularly likely in operations involving revascularization for coronary artery disease. Causes include incomplete myocardial preservation during CPB, particulate or air emboli in a coronary graft or a native coronary artery, coronary spasm, coronary thrombosis, technical surgical problems such as kinking of a graft or compromised graft anastomosis, or incomplete revascularization secondary to distal disease or inoperable vessels. Transesophageal echocardiography (TEE) is employed to assess global LV function as well as regional wall motion abnormalities that may be associated with specific graft or vessel compromise. (See  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Mechanical complications'</a>.)</p><p>After reversible surgical factors are investigated and addressed, interventions by the anesthesiologist should focus on optimizing HR, pacing mode, and vasoactive drug therapy.</p><p class="headingAnchor" id="H856462958"><span class="h3">Vasoactive drug therapy</span><span class="headingEndMark"> — </span>Usually, LV dysfunction will improve with inotropic drug therapy or combination therapy with positive inotropic and vasodilator agents to optimize cardiac index (CI) [<a href="#rid3">3-6</a>]. Initially, small boluses of <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> (5 to 10 mg) or diluted <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (5 to 10 mcg) may be administered to treat ventricular dysfunction and hypotension; if necessary, one or more vasoactive infusions are initiated  (<a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/90614.html" rel="external">"Weaning from cardiopulmonary bypass", section on 'Maintenance of optimal pacemaker function'</a> and  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Poor inotropy'</a>.)</p><p>For inotropic support, infusions of sympathomimetic amines (eg, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) are commonly used as first-line therapies, alone or in combination with <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">milrinone</a> [<a href="#rid3">3,7,8</a>]. The inodilator milrinone is a phosphodiesterase inhibitor that produces positive inotropic effects by slowing hydrolysis of cyclic adenosine monophosphate and works independently of beta-adrenergic receptors [<a href="#rid5">5,6,9-12</a>]. Since administration of milrinone may result in significantly reduced SVR, concomitant use of an arterial vasoconstrictor (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>, norepinephrine, epinephrine) may be necessary. Selection of a first-line inotropic agent depends on the individual patient's hemodynamic abnormalities during the weaning process  (<a class="graphic graphic_table graphicRef93595" href="/z/d/graphic/93595.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">table 2</a>), as well as institutional preferences [<a href="#rid3">3,4,7,8,13-15</a>]. Alternate inotropic agent(s) may be selected as conditions change during the postbypass period. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p>In patients who are hypertensive during weaning from bypass, <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> is typically administered if ischemia is suspected, while <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">clevidipine</a>, <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">milrinone</a>, or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> may be helpful to reduce afterload in patients without ischemia. There are marked institutional variations in the selection of specific vasoactive agents and combinations of agents [<a href="#rid7">7,8,13,15-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/90614.html" rel="external">"Weaning from cardiopulmonary bypass", section on 'Maintenance of optimal pacemaker function'</a> and  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Poor inotropy'</a>.)</p><p>Levosimendan is an inodilator that increases myocardial sensitivity to calcium, which increases cardiac contractility and opens adenosine triphosphate channels in vascular smooth muscle causing vasodilation [<a href="#rid18">18</a>]. In countries where it is available, levosimendan is often used during weaning from CPB and/or in the postoperative period in cardiac surgical patients [<a href="#rid19">19</a>]. While meta-analyses that included mainly small trials have suggested a benefit of levosimendan on survival and adverse events in patients with low ejection fraction (EF) &lt;40 percent after cardiac surgery, data have been limited by heterogeneity and risk of bias [<a href="#rid19">19,20</a>]. The largest randomized multicenter trial was conducted in 849 cardiac surgical patients; prophylactic levosimendan administration (with infusion initiated shortly before surgery and continued for 23 hours) did not result in a lower rate of death, perioperative myocardial infarction, renal replacement therapy (RRT), or use of a ventricular assist device (VAD) compared with placebo [<a href="#rid21">21</a>]. Another randomized trial in 506 patients was stopped early for futility, failing to show a benefit for levosimendan administered for up to 48 hours after cardiac surgery [<a href="#rid22">22</a>]. However, limited evidence in subgroup trials indicates possible benefit in patients with low preoperative EF [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H4249362767"><span class="h3">Controversies regarding use of inotropic drug therapy</span><span class="headingEndMark"> — </span>We do not prophylactically or routinely administer an inotropic agent [<a href="#rid24">24</a>]. Administration of inotropic and other vasoactive agents after cardiac surgery is based on achieving short-term hemodynamic goals, particularly in patients with low preoperative LV EF (eg, &lt;30 percent) [<a href="#rid3">3,13</a>]. Outcome benefits versus harms are unclear, and some data suggest that perioperative use of inotropes is associated with increased postoperative mortality and morbidity in cardiac surgical patients [<a href="#rid13">13,25-27</a>]. As an example, in one observational study using propensity score matching, perioperative use of inotropes was independently associated with more than threefold increased mortality (adjusted hazard ratio [HR] 3.7, 95% CI 2.1-6.5) [<a href="#rid13">13</a>]. However, the investigators acknowledged that use of inotropic therapy may be the only option for weaning from CPB in some cases.</p><p class="headingAnchor" id="H1316232688"><span class="h2">Left ventricular diastolic dysfunction</span><span class="headingEndMark"> — </span>Diastolic dysfunction (ie, restrictive filling with impaired ability of the LV to fully accommodate the returning venous blood volume due to impaired relaxation of the myocardium or pericardium) may be caused by LV preexisting conditions such as hypertrophy, fibrosis, infiltrative disease, or pericardial constriction. Diastolic dysfunction often occurs in conjunction with systolic dysfunction, but is present in some patients who have preserved LV systolic function and EF. Diastolic dysfunction. Furthermore, intraoperative acute ischemia, hypoxia, or cellular calcium overload may also result in functional cellular abnormalities of myocyte relaxation and new diastolic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">"Pathophysiology of heart failure with preserved ejection fraction"</a>.)</p><p>Weaning from CPB may be challenging in patients with diastolic dysfunction. The following considerations are applicable [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Euvolemia should be maintained. Appropriate interpretation of ventricular filling pressures (eg, central venous pressure (CVP) or pulmonary artery wedge pressure [PAWP]) is important since patients with diastolic dysfunction may have abnormally increased filling pressures for any given LV or RV filling volume. As a result, transient and abrupt elevation in filling pressures should not be overtreated with excessive diuresis or preload reduction that may result in precipitous hypotension. However, excessive volume administration may precipitate pulmonary edema due to impaired LV compliance. (See  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Inadequate preload'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimal HR should be maintained with atrial or AV sequential pacing at 80 to 90 beats per minute (bpm). Occasionally, a slightly faster HR of 90 to 100 bpm is selected (eg, for patients with frequent premature atrial contractions [PACs] to best maintain a stable rhythm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AV synchrony should be maintained, since the atrial contribution to ventricular filling may exceed 30 percent, particularly in patients with early stage (Grade 1) diastolic dysfunction (see  <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults", section on 'Grading diastolic dysfunction'</a>). Atrial pacing or AV sequential pacing may be needed to achieve this goal.</p><p></p><p class="headingAnchor" id="H3047556847"><span class="h2">Right ventricular dysfunction</span><span class="headingEndMark"> — </span>RV dysfunction may complicate weaning from CPB [<a href="#rid1">1</a>]. Dysfunction may be preexisting, or caused or exacerbated by pulmonary hypertension, RV ischemia or infarct, intracoronary or pulmonary air embolism, or tricuspid regurgitation [<a href="#rid29">29</a>]. Intracardiac air, always present to some degree following open left-sided cardiac procedures, preferentially enters the right coronary artery (RCA) due to its more anterior (non-dependent) position in the supine patient and often results in RV dysfunction.</p><p>RV dysfunction manifests as increased CVP with systemic hypotension due to reduced functional LV preload. Severe RV dysfunction may also compromise LV perfusion. On direct inspection, the RV appears distended and shows poor contractility. TEE examination reveals severe RV hypokinesis often accompanied by significant tricuspid regurgitation. Also, the interventricular septum may be shifted towards the left, thereby impairing filling of the LV and resulting in increased left-sided filling pressures (ie, PAWP) despite inadequate LV filling volume. Leftward septal shift during diastole indicates RV volume overload, while leftward septal shift during systole indicates RV pressure overload. Some clinicians use RV pressure waveform analysis to facilitate diagnosis of systolic and diastolic RV dysfunction [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart"</a>.)</p><p>Management includes ensuring that BP and coronary perfusion pressure are adequate, as well as preventing increased pulmonary vascular resistance (PVR), which can be caused by hypoxemia, hypercarbia, acidosis, hypothermia, or pain. Excessive administration of fluid is avoided, as this may worsen RV dysfunction. Pharmacologic therapies for RV dysfunction provide inotropic support with intravenous agents that produce pulmonary arterial vasodilation (eg, <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">milrinone</a>, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>) [<a href="#rid31">31</a>]. Levosimendan has also been used to support the RV in this setting [<a href="#rid32">32</a>]. Typically, such agents are combined with administration of vasopressor therapy (eg, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) to maintain systemic perfusion pressure.</p><p>In refractory RV failure, continuous inhalation of an aerosolized vasodilator to treat pulmonary hypertension and reduce RV afterload is reasonable [<a href="#rid1">1</a>]. Typical agents and doses are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitric oxide</strong> – Administration of 5 to 20 parts per million (ppm) requires a nitric oxide administration apparatus, a nitric oxide gas analyzer, and a nitrogen dioxide gas analyzer, as well as a specially trained health care professional. Doses &gt;20 ppm should be used with caution; doses &gt;40 ppm provide minimal additional clinical benefit. Adverse effects of high doses administered for prolonged periods include development of methemoglobinemia and abrupt discontinuation may cause rebound pulmonary hypertension. (See  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epoprostenol</strong> – Administration of <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> is accomplished via a nebulizer in the ventilator circuit; typical doses in the postbypass setting are 30 to 50 ng/kg/minute [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Milrinone</strong> – Inhaled <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">milrinone</a> has been used for acute RV failure in several studies; although apparently safe, its efficacy in treating acute RV failure or pulmonary hypertension via this route of administration is uncertain [<a href="#rid12">12,34</a>].</p><p></p><p>Meta-analyses conducted in 2017, 2018, and 2019 have not shown benefits in clinical outcomes when inhaled aerosolized pulmonary vasodilators were employed during cardiac surgery compared with intravenously administered agents [<a href="#rid12">12,35,36</a>].</p><p>In rare cases of severe RV dysfunction, a patient may require a temporary mechanical RV assist device.</p><p class="headingAnchor" id="H2316445104"><span class="h2">Vasoplegia</span><span class="headingEndMark"> — </span>Severe systemic vasodilation (vasoplegia, vasodilatory shock) with markedly decreased SVR may become evident during or after CPB in 5 to 25 percent of patients undergoing cardiac surgery, and may cause severe persistent postbypass and postoperative hypotension despite a normal or increased CI [<a href="#rid37">37-41</a>]. Risk factors for vasoplegia include preoperative use of certain medications (eg, angiotensin-converting enzyme [ACE] inhibitors, heparin, calcium channel blockers, diuretics), patient-related factors such as dialysis-dependent renal failure or recent myocardial infarction, and procedure-related factors such as prebypass hemodynamic instability, insertion of a left ventricular assist device, or need for valve surgery [<a href="#rid37">37,38,40,42,43</a>].</p><p>Agents used for treatment include <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> and <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>. Most patients with vasodilatory shock respond to hemodynamic-guided IV fluid therapy and/or IV norepinephrine, often at low doses [<a href="#rid44">44,45</a>]. However, adding or substituting vasopressin may be necessary for effective treatment when vasoplegia is refractory to catecholamines [<a href="#rid40">40,46</a>]. In a 2018 meta-analysis of eight trials that included 625 patients undergoing cardiac surgery, use of vasopressin reduced risk of vasodilatory shock (odds ratio [OR] 0.4, 95% CI 0.16-0.97), atrial fibrillation (OR 0.42, 95% CI 0.21-0.82), and overall perioperative complications (OR 0.33, 95% CI 0.20-0.54), compared with standard therapy or placebo [<a href="#rid47">47</a>]. Another 2018 meta-analysis in critically ill patients with distributive shock also noted that the addition of vasopressin to catecholamine therapy was associated with lower rates of atrial fibrillation compared with administration of catecholamines alone (risk ratio [RR] 0.77, 95% CI, 0.67-0.88) [<a href="#rid48">48</a>].</p><p>Other agents that have been used to treat refractory vasoplegia include <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a>, angiotensin II, <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, or hydroxycobalamin  (<a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">table 3</a>) [<a href="#rid23">23,39,46,49-64</a>]. Further discussion of management of vasoplegia during and after CPB is available in other topics. (See  <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Management of hypotension'</a> and  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Vasodilatory shock'</a>.)</p><p class="headingAnchor" id="H3208974280"><span class="h2">Arrhythmias</span><span class="headingEndMark"> — </span>Both supraventricular and ventricular arrhythmias are common during and after weaning from CPB. Normal sinus rhythm is ideal because it provides an atrial contribution to ventricular filling and normal, synchronized contraction of the ventricles.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular arrhythmias</strong> – Ventricular fibrillation during weaning or the postbypass period should be immediately treated with defibrillation. In the open chest, internal paddles are applied directly to the heart to deliver 10 to 20 joules of electricity. If ventricular arrhythmias persist or recur, an antiarrhythmic drug infusion, usually <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, is initiated. (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias"</a> and  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Amiodarone for ventricular arrhythmias'</a>.)</p><p></p><p class="bulletIndent1">Factors such as hypokalemia and hypomagnesemia that may contribute to development of arrhythmia are corrected. Persistent or recurrent ventricular fibrillation may indicate myocardial ischemia and inadequacy of coronary blood flow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation</strong> – Atrial fibrillation (AF) is the most common arrhythmia after cardiac surgery but usually develops two to five days postoperatively rather than in the immediate postbypass period. AF or atrial flutter that occurs in the immediate postbypass period can often be converted to normal sinus rhythm with synchronized cardioversion, especially if sinus rhythm was present before CPB [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias"</a> and  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p></p><p class="bulletIndent1">If cardioversion is unsuccessful, a reasonable option is <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> 150 mg bolus IV administered over 10 minutes and followed by continuous infusion at 1 mg/minute. If rate control is necessary, <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, or <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> may be administered [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a> and  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Intravenous amiodarone for the treatment of atrial arrhythmias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bradycardia</strong> – If sinus bradycardia, complete heart block, or asystole develops, temporary pacing via surgically placed epicardial wires should be instituted. Sinus bradycardia is preferentially treated by atrial pacing. However, if heart block is present, AV sequential pacing is employed to maintain atrioventricular synchrony, which promotes adequate filling of the LV.</p><p></p><p class="bulletIndent1">If there is no organized atrial rhythm (eg, AF) and HR is slow, then ventricular pacing must be used. In such cases, absence of AV synchrony limits CI, particularly in patients with diastolic dysfunction and reduced LV compliance.</p><p></p><p class="bulletIndent1">When bradycardia or heart block is dependent on external pacing, the capture threshold of the pacemaker should be assessed. High thresholds should prompt wire replacement, repositioning, or placement of a second set of wires in the case of pacemaker failure. (See  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Dysrhythmias'</a>.)</p><p></p><p class="bulletIndent1">Biventricular pacing has been demonstrated to improve cardiac output during weaning from CPB in patients with heart failure, compared with standard pacing, but is more complex and not commonly employed in this setting [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H640553448"><span class="h2">Arterial air embolization</span><span class="headingEndMark"> — </span>Air may accumulate in the left heart chambers during procedures such as aortic or mitral valve repair or replacement. Even procedures not typically associated with opening the left heart chambers may be associated with entrainment of air, including injury associated with ligation of the left atrial appendage. Intracardiac air may embolize to the coronary, cerebral, and peripheral circulations once the aortic cross-clamp is removed and the heart begins to contract  (<a class="graphic graphic_movie graphicRef114097 graphicRef114100 graphicRef114098 graphicRef114099" href="/z/d/graphic/114097.html" rel="external">movie 1A-D</a>). Since the RCA is in an anterior or nondependent position when a patient is supine, air preferentially enters the RCA causing ischemia of the inferior LV wall and the RV  (<a class="graphic graphic_movie graphicRef114097" href="/z/d/graphic/114097.html" rel="external">movie 1A</a>), as well as arrhythmias, particularly heart block. Air microembolization to the cerebral circulation may cause neurologic dysfunction as well as seizures [<a href="#rid68">68</a>].</p><p>TEE is employed to identify air in the heart during the weaning process and guide its removal by surgical venting of the LV or aortic root, thereby preventing massive arterial air embolism. Inotropic or vasopressor drug treatment may be necessary to increase BP and improve coronary perfusion until residual air has been cleared from the heart and coronary vessels.</p><p class="headingAnchor" id="H3168187029"><span class="h2">Surgical or technical problems</span><span class="headingEndMark"> — </span>Surgical or technical problems resulting in myocardial ischemia are a rare cause of difficulty in weaning. Examples include poor quality of a coronary bypass graft anastomosis or kinking of the graft, embolization of air or microparticulate debris into a native coronary artery or graft, or suture ligation or injury of a coronary artery during aortic valve, aortic root, or mitral valve replacement. In such cases, myocardial ischemia is identified by ventricular wall motion abnormalities noted on TEE examination, as well as hypotension and low cardiac output (CO) despite high doses of inotropic and/or vasopressor agents, and/or ST-segment changes on the electrocardiogram (ECG). Poor coronary graft flow after coronary revascularization procedures may be confirmed with a Doppler flow probe applied to the graft. (See  <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery", section on 'Mechanical complications'</a>.)</p><p>Iatrogenic aortic dissection is a rare complication of cardiac surgery; a retrospective report described seven cases among 3000 cardiac surgical procedures in a single institution [<a href="#rid69">69</a>]. Aortic dissection usually occurred due to aortic cannulation and was detected at the onset of CPB (see  <a class="medical medical_review" href="/z/d/html/115759.html" rel="external">"Initiation of cardiopulmonary bypass", section on 'Aortic cannulation'</a>), but is sometimes diagnosed with TEE at the end of bypass  (<a class="graphic graphic_diagnosticimage graphicRef120106" href="/z/d/graphic/120106.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef134844" href="/z/d/graphic/134844.html" rel="external">image 2</a>) (see  <a class="medical medical_review" href="/z/d/html/90607.html" rel="external">"Anesthesia for coronary artery bypass grafting surgery", section on 'Postbypass transesophageal echocardiography'</a>). Further TEE assessment should include the anatomic location and extent of the dissection and whether there is concomitant involvement of the aortic valve. Additional discussion of the surgical and anesthetic management of this condition is available separately. (See  <a class="medical medical_review" href="/z/d/html/94292.html" rel="external">"Anesthesia for aortic surgery with hypothermia and elective circulatory arrest in adult patients", section on 'Considerations for emergency surgery for acute aortic dissection'</a> and  <a class="medical medical_review" href="/z/d/html/16166.html" rel="external">"Surgical and endovascular management of acute type A aortic dissection", section on 'Surgical repair'</a>.)</p><p class="headingAnchor" id="H1602145336"><span class="h2">Left ventricular outflow tract obstruction</span><span class="headingEndMark"> — </span>LV outflow tract (LVOT) obstruction can occur when the outflow tract is narrowed by LV septal hypertrophy and/or abnormal length and positioning of the mitral valve leaflets. The resultant systolic mitral leaflet-septal contact causes mechanical obstruction to LV ejection, as well as mitral regurgitation due to inadequate coaptation of the mitral valve leaflets  (<a class="graphic graphic_diagnosticimage graphicRef102345" href="/z/d/graphic/102345.html" rel="external">image 3</a> and <a class="graphic graphic_movie graphicRef93358" href="/z/d/graphic/93358.html" rel="external">movie 2</a>) [<a href="#rid70">70</a>]. Such LVOT obstruction may be preexisting or may occur after mitral valve repair, aortic valve replacement, and other cardiac operations in patients with severe underlying left ventricular hypertrophy.</p><p>LVOT obstruction is dynamic. Because a hypertrophied LV has reduced compliance and is extremely sensitive to changes in preload and afterload, hypovolemia or reduced SVR will worsen obstruction. Since tachycardia or a hypercontractile state will also worsen obstruction, administration of sympathomimetic drugs to treat hypotension is contraindicated.</p><p>Treatment of hemodynamically significant LVOT obstruction includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing LV volume with fluid administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing SVR with vasoconstrictors that do not have inotropic or chronotropic properties (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> or <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreasing inotropy and HR with anesthetic agents or beta-blockers. Epicardial pacing can maintain an adequate HR when these therapies cause bradycardia.</p><p></p><p>TEE interpretation is critical for identification of LVOT obstruction and optimal intraoperative management because standard cardiovascular monitoring will not reveal the underlying cause of hypotension and often leads to inappropriate therapy. For example, systemic hypotension with low CO and mitral regurgitation is often treated with inotropic agents, but such treatment only worsens LVOT obstruction and further decreases BP. Also, TEE assessment of the mechanism causing LVOT obstruction may lead to a surgical decision to reinstitute CPB to revise a mitral valve repair or perform ventricular septal myectomy.</p><p class="headingAnchor" id="H3093503226"><span class="h2">Cardiogenic shock</span><span class="headingEndMark"> — </span>Postcardiotomy cardiogenic shock occurs in 0.2 to 6.0 percent of patients after cardiac surgery with CPB, with inability to maintain oxygenation, adequate CO, or end-organ perfusion [<a href="#rid71">71,72</a>]. Temporary mechanical circulatory support (eg, intraaortic balloon pump [IABP] counterpulsation, percutaneous or implantable VAD, extracorporeal membrane oxygenation [ECMO]) may be employed in cases of refractory ventricular dysfunction resulting in persistently low CO [<a href="#rid71">71</a>]. Selection of a circulatory assist device depends on individual patient hemodynamic factors, surgical preferences, and institutional resources  (<a class="graphic graphic_table graphicRef116235" href="/z/d/graphic/116235.html" rel="external">table 4</a>). Contraindications and complications associated with all temporary mechanical support devices are listed in the table  (<a class="graphic graphic_table graphicRef119277" href="/z/d/graphic/119277.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H4274257778"><span class="h3">Short-term mechanical circulatory assist devices</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraaortic balloon pump </strong>– IABP counterpulsation is a mainstay for treatment of failure to wean from CPB, with between 14 and 28 percent of all IABP use occurring after CPB [<a href="#rid73">73-79</a>]. Several studies have been performed assessing the effectiveness of an IABP during weaning from CPB, with in-hospital mortality ranging from 20 to 34 percent [<a href="#rid73">73,76-79</a>]. In various studies, risk factors for mortality have included high vasopressor doses, mixed venous saturation &lt;60 percent, higher left atrial pressure or LVEDP, higher preoperative creatinine, longer aortic cross-clamp duration, and urgent/emergency surgery. Other complications include limb ischemia, vascular injury, and, rarely, significant hemorrhage. Risk factors for complications include peripheral artery disease, older age, female sex, small body surface area &lt;1.8 m<sup>2</sup>, larger catheter size (&gt;9.5 French), diabetes mellitus, hypertension, prolonged need for IABP support, and CI &lt;2.2 L/minute/m<sup>2</sup>. (See  <a class="medical medical_review" href="/z/d/html/1482.html" rel="external">"Intraaortic balloon pump counterpulsation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular assist devices </strong>–<strong> </strong>A temporary VAD can provide circulatory support and allow time for myocardial recovery [<a href="#rid80">80</a>]. In rare instances, the VAD is inserted to serve as a bridge to urgent cardiac transplantation [<a href="#rid80">80-82</a>]. Efficacy of VADs for management of cardiogenic shock developing during cardiac surgery has been demonstrated in case reports and small clinical trials [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices"</a>.)</p><p></p><p>Ideally, TEE or fluoroscopy guidance is used to confirm the indication for support placement, evaluate for contraindications to a particular device, and confirm proper placement of inflow and outflow cannulae and the device itself, as well as to assess device function after placement, as discussed in detail in a separate topic. Findings such as aortic dissection may necessitate continuation of medical management while a safe cannulation strategy for mechanical support is implemented  (<a class="graphic graphic_diagnosticimage graphicRef134844" href="/z/d/graphic/134844.html" rel="external">image 2</a>). (See  <a class="medical medical_review" href="/z/d/html/127006.html" rel="external">"Short-term left ventricular mechanical circulatory support: Use of echocardiography during initiation and management"</a>.)</p><p class="headingAnchor" id="H667596731"><span class="h3">Extracorporeal membrane oxygenation</span><span class="headingEndMark"> — </span>ECMO can provide both hemodynamic and respiratory support for patients with postcardiotomy cardiogenic shock that cannot be managed with drugs and changes in ventilation strategies. Components of an ECMO circuit include the gas exchange unit (oxygenator/heater), driving force (pump), and tubing. Similar to CPB, ECMO can support oxygenation, ventilation, circulation, heating, and cooling, but unlike CPB, ECMO lacks the ability to administer fluids directly via the circuit. Typically, ECMO is easier to establish than mechanical ventricular support with an Impella VAD and allows higher flow rate (up to 10 L/minute). (See  <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices", section on 'Extracorporeal membrane oxygenation'</a> and  <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Venoarterial (VA) ECMO involves drainage of blood from the venous system to an oxygenator-ventilator (artificial lung), with return of blood to the systemic system. VA ECMO effectively removes carbon dioxide and supplies oxygen and supports both the right and left ventricles. Blood flow through the lungs is minimized with effective VA ECMO. Thus, VA ECMO may be utilized to treat left or right heart failure, and supports oxygenation and carbon dioxide removal if respiratory failure is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venovenous (VV) ECMO involves drainage of blood from the venous system to an oxygenator-ventilator (artificial lung), with return of the oxygenated blood to the right side of the heart where it passes through the lungs, left side of the heart, and eventually into the systemic circulation  (<a class="graphic graphic_figure graphicRef56622" href="/z/d/graphic/56622.html" rel="external">figure 2</a>). As such, it provides support for refractory respiratory failure (eg, non-cardiogenic pulmonary edema associated with protamine reactions, transfusion-related acute lung injury, acute respiratory distress syndrome), but not for cardiogenic shock. [<a href="#rid85">85</a>].</p><p></p><p>Cannulation for ECMO may be either peripheral or central  (<a class="graphic graphic_diagnosticimage graphicRef116518" href="/z/d/graphic/116518.html" rel="external">image 4</a>), typically with TEE guidance, as described in detail in a separate topic (see  <a class="medical medical_review" href="/z/d/html/131002.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: The role of transesophageal echocardiography (TEE)"</a>). Advantages to peripheral cannulation include ease of chest closure and removal of cannulae, as well as the fact that peripheral cannulae are generally more secure (less likely to dislodge) than central cannulae. However, central cannulation for VV or VA ECMO is often easier, allows larger cannula, and eliminates risk of femoral venous or arterial complications, including peripheral ischemia associated with a large cannula in the femoral artery. The major disadvantage is that central cannula is less secure and dislodgement may cause life-threatening hemorrhage.</p><p>Initial settings for ECMO include a target blood flow rate of 60 mL/kg/minute in patients with minimal cardiac function [<a href="#rid86">86</a>]. Mean arterial pressure should be maintained between 65 and 80 mmHg [<a href="#rid86">86</a>]. Once the patient is stable and not bleeding, heparin may be administered to keep the partial thromboplastin time at approximately 1.5 to 2 times normal [<a href="#rid87">87</a>].</p><p>Two 2018 meta-analyses of observational studies in patients who received ECMO for postcardiotomy cardiogenic shock (one that included 31 studies and 2986 patients and the other with 20 studies and 2877 patients) have noted that approximately one-third survive to hospital discharge [<a href="#rid88">88,89</a>]. Factors associated with survival in these meta-analyses included younger age and lower baseline blood lactate levels. Prediction of outcome after ECMO insertion in this setting is challenging due to heterogeneity of specific patient- and procedure-related reasons for failure to wean from CPB.</p><p class="headingAnchor" id="H3931748694"><span class="h2">Early post-bypass cardiac arrest</span><span class="headingEndMark"> — </span>Cardiac arrest may occur at any time in the postbypass period, usually in the first five postoperative hours [<a href="#rid90">90,91</a>]. In one series of 3982 patients undergoing cardiac surgery, the incidence was 0.7 percent in the first 24 hours after surgery [<a href="#rid92">92</a>].</p><p>Arrest immediately after cardiopulmonary bypass may be the result of delayed entry of air into the coronary circulation resulting in ischemia, sudden onset massive bleeding, loss of pacing capability in patients that are dependent upon a pacemaker, as well as drug and management errors. Prolonged duration of CPB, low CI, myocardial ischemia, mechanical impediments to cardiac function (eg, tamponade or graft inadequacy), and major bleeding are predictors of cardiac arrest [<a href="#rid90">90-92</a>].</p><p class="headingAnchor" id="H1317542222"><span class="h1">PULMONARY PROBLEMS</span></p><p class="headingAnchor" id="H2276895061"><span class="h2">Airway obstruction</span><span class="headingEndMark"> — </span>Airway occlusion, bronchospasm, and respiratory insufficiency may result in hypoxemia, inadequate ventilation, and increased airway pressures, as well as increased pulmonary vascular resistance with resultant right ventricular (RV) dysfunction.</p><p>The anesthesiologist should be aware of any difficulties in ventilating the lungs before attempting to wean from CPB. Both lungs should be expanded with positive pressure ventilation, and appropriate lung inflation should be confirmed by direct observation in the open chest. The differential diagnosis of poor lung inflation and/or deflation includes airway obstruction (eg, kinked endotracheal tube [ETT], tracheal or bronchial obstruction [eg, mucous plug], airway compression by the transesophageal echocardiography [TEE] probe), right mainstem intubation, or pulmonary aspiration. Blood in the airway is uncommon, but may occur due to pulmonary parenchymal injury, pulmonary artery rupture caused by a pulmonary artery catheter (PAC), or injury during pulmonary thromboendarterectomy.</p><p>An initial step for evaluation of airway obstruction is to pass a flexible suction catheter into the ETT. If obstruction does not resolve after aspiration of secretions, bronchospasm is likely and should be treated. In some cases, flexible bronchoscopy may be necessary.</p><p class="headingAnchor" id="H2487735150"><span class="h2">Bronchospasm</span><span class="headingEndMark"> — </span>Bronchospasm during weaning from CPB may be due to an allergic drug reaction (eg, protamine) or transfusion reaction (eg, blood products, plasma expanders), hypothermia, inadequate anesthesia, or preexisting asthma or chronic obstructive pulmonary disease [<a href="#rid93">93</a>]. Bronchospasm is managed by administering bronchodilating pharmacologic agents. Depth of anesthesia is also evaluated because bronchospasm may result from inadequate anesthesia [<a href="#rid94">94</a>]. First-line therapies are inhaled beta<sub>2</sub> agonists such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> and/or low doses of intravenous (IV) <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> administered initially in 5 to 10 mcg boluses, increasing up to 100 mcg per bolus and/or an infusion at 2 to 10 mcg/minute if necessary  (<a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">table 6</a>). Also, H1 and H2 antihistamines are administered to reverse the effects of mediator release. In severe cases, steroids such as <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> or <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> are administered to decrease airway swelling and reduce likelihood of recurrence. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Initial management'</a>.)</p><p>If these interventions are not successful, it may be necessary to re-establish CPB.</p><p class="headingAnchor" id="H3455127331"><span class="h2">Pulmonary edema</span><span class="headingEndMark"> — </span>Cardiogenic pulmonary edema may be due to preexisting or new-onset heart failure exacerbated by additional fluid administration during CPB. Hemoconcentration during CPB and diuresis during and after CPB minimize the likelihood of this complication.</p><p>Noncardiogenic pulmonary edema may be caused by protamine, transfusion-related acute lung injury, or other causes of acute respiratory distress syndrome (see  <a class="medical medical_review" href="/z/d/html/90614.html" rel="external">"Weaning from cardiopulmonary bypass", section on 'Reversal of anticoagulation with protamine'</a> and  <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>). Also, prolonged CPB duration &gt;4 hours is associated with noncardiogenic pulmonary edema due to sequestration of neutrophils in the pulmonary capillaries, elevation of lysosomal enzyme activity, localized inflammatory response, and, ultimately, increased capillary permeability [<a href="#rid95">95</a>].</p><p>Treatment involves administration of a diuretic such as <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>. In patients with severely elevated pulmonary artery pressure, continuous inhalation of nitric oxide or <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> is reasonable. In rare cases of severe pulmonary edema, extracorporeal membrane oxygenation (ECMO) is necessary to temporarily replace lung function. (See <a class="local">'Right ventricular dysfunction'</a> above and  <a class="medical medical_review" href="/z/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a>.)</p><p class="headingAnchor" id="H710622944"><span class="h1">BLEEDING AND COAGULOPATHY</span><span class="headingEndMark"> — </span>Bleeding necessitating transfusion occurs commonly after cardiac surgery with CPB [<a href="#rid96">96</a>]. Risk factors include preexisting coagulopathy or anticoagulant therapy, advanced age, small body surface area, female gender, need for repeat sternotomy, and urgent or emergency procedures [<a href="#rid97">97</a>]. Specific causes of excessive bleeding during and after weaning from CPB include inadequate surgical hemostasis, loss of platelets and coagulation factors due to persistent surgical bleeding, effects of hemodilution, hypothermic coagulopathy, presence of residual heparin, coagulopathy due to platelet activation (and consumption), and hyperfibrinolysis induced by the extracorporeal circuit. Management of bleeding and coagulopathy after CPB is addressed in detail in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Achieving hemostasis and management of bleeding'</a>.)</p><p class="headingAnchor" id="H3010010467"><span class="h1">METABOLIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Metabolic disturbances after CPB are common and are associated with arrythmias and hemodynamic instability.</p><p class="headingAnchor" id="H2991969927"><span class="h2">Hypocalcemia</span><span class="headingEndMark"> — </span>Hypocalcemia is common following CPB and is corrected with <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a> (5 to 10 mg/kg) or, less commonly, <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a> (250 to 1000 mg) during or shortly after separation from CPB. To reduce the risk of reperfusion injury following bypass, treatment is delayed for at least 10 to 15 minutes after removal of the aortic cross-clamp, thus allowing a period of myocardial reperfusion [<a href="#rid98">98</a>].</p><p>After separation from CPB, calcium should be immediately available to treat hypocalcemia and/or hyperkalemia. Although <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a> transiently improves systolic function and increases systemic vascular resistance (SVR) [<a href="#rid99">99,100</a>], we do not routinely administer calcium after separation from CPB because of the possibility of increased reperfusion injury [<a href="#rid101">101</a>], increased ventricular wall stiffness [<a href="#rid100">100</a>], or induced spasm of the internal mammary artery graft [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H650407535"><span class="h2">Hypokalemia</span><span class="headingEndMark"> — </span>Hypokalemia may contribute to increased cardiac automaticity, leading to development of atrial or ventricular arrhythmias. Causes of hypokalemia during weaning include preoperative diuretic therapy, <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> administration during CPB, and treatment of hyperglycemia with insulin administration. Hypokalemia in the postbypass period is corrected by infusion of potassium 10 to 20 mEq over 30 minutes. A central catheter and full continuous hemodynamic monitoring are necessary during such rapid administration. (See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Recommended approach'</a>.)</p><p class="headingAnchor" id="H1496370094"><span class="h2">Hyperkalemia</span><span class="headingEndMark"> — </span>Hyperkalemia may result from potassium cardioplegia or extracellular shifts associated with respiratory or metabolic acidosis. It is more likely to be a clinical problem in patients with impaired kidney function. If severe, it can interfere with cardiac conduction.</p><p>A reasonable approach to management includes moderate hyperventilation and, if necessary, administration of calcium, a combination of glucose and insulin, or both. Other treatments include beta-agonists to facilitate intracellular migration of potassium, or <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> to eliminate potassium via diuresis. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Patients with a hyperkalemic emergency'</a>.)</p><p class="headingAnchor" id="H2531289469"><span class="h2">Hypomagnesemia</span><span class="headingEndMark"> — </span>Hypomagnesemia after CPB may be associated with postoperative dysrhythmias, myocardial ischemia, and ventricular dysfunction [<a href="#rid103">103,104</a>]. Causes include hemodilution with magnesium-free fluids during CPB, as well as diuresis. When hypomagnesemia is confirmed via laboratory analysis or is suspected due to arrhythmias (eg, atrial fibrillation [<a href="#rid105">105</a>]), intravenous (IV) magnesium is administered (1 to 2 g over 15 minutes). Administration of magnesium may result in hypotension [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/z/d/html/834.html" rel="external">"Hypomagnesemia: Evaluation and treatment"</a>.)</p><p class="headingAnchor" id="H1196504902"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>We agree with the Society of Thoracic Surgeons (STS) guidelines, which recommend maintaining the blood glucose level at &lt;180 mg/dL (10 mmol/L) during CPB and the postbypass period with IV insulin administered as small bolus doses or a continuous insulin drip if necessary [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p>Hyperglycemia is extremely common during and after CPB. Poor perioperative glycemic control has been associated with increased morbidity and mortality [<a href="#rid108">108</a>]. However, attenuating the hyperglycemic response to cardiac surgery and CPB is difficult, and tight control can be harmful [<a href="#rid109">109</a>]. In a randomized trial of 400 cardiac surgical patients receiving either "tight," glucose control during the intraoperative period (ie, use of IV insulin infusion to attempt to maintain intraoperative glucose levels at 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) or conventional management (ie, maintenance of glucose level &lt;200 mg/dL [11.1 mmol/L]), the rate of stroke was significantly higher in the tight-control group [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H116273342"><span class="h1">OLIGURIA</span><span class="headingEndMark"> — </span>Urine output (UO) is measured approximately every 30 minutes in the postbypass period. Ideally, UO is ≥0.5 mL/kg per hour. However, interventions and events occurring during and after CPB may result in increased UO (eg, <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a>) or decreased UO (eg, hemoconcentration, ischemia-reperfusion injury). Also, ongoing effects of anesthesia and surgery may temporarily reduce glomerular filtration, renal tubular function, and UO [<a href="#rid111">111</a>]. If UO is &lt;0.5 mL/kg, we check the bladder catheter for kinking or disconnection, use transesophageal echocardiography (TEE) to exclude aortic dissection as a possible cause of renal hypoperfusion, administer adequate intravascular volume to ensure euvolemia, and maintain adequate cardiac index (CI; ie, &gt;2.0 L/minute per m<sup>2</sup>). We do not administer an infusion of "renal dose" <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> or other pharmacologic agents, as this is not effective for renal protection [<a href="#rid112">112,113</a>].</p><p class="headingAnchor" id="H1654633370"><span class="h1">HYPOTHERMIA</span><span class="headingEndMark"> — </span>A decrease in the core temperature after rewarming from hypothermic CPB is termed "afterdrop" and is seen in most patients following weaning from bypass [<a href="#rid114">114</a>]. (See  <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Temperature'</a>.)</p><p>Measures to prevent and treat hypothermia include adequate rewarming prior to separation from CPB (see  <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Management during rewarming and weaning'</a>), increasing the room temperature, warming cold blood products during transfusion, and use of patient warming devices that employ forced air or circulating fluid [<a href="#rid115">115</a>]. Supplementary methods such as warming of intravenous (IV) fluids and breathing system humidifiers are less effective [<a href="#rid116">116</a>]. Continuation of active warming is essential for patients who are hypothermic upon arrival in the intensive care unit.</p><p>Hypothermia may cause or exacerbate decreased myocardial function due to ischemia, as well as bleeding due to platelet dysfunction, and it decreases metabolism of intravenously administered drugs (see  <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Consequences'</a>). However, temporary mild hypothermia is common postoperatively and appears to have few consequences. Approximately one-half of patients undergoing coronary artery bypass grafting (CABG) surgery with CPB remained hypothermic (&lt;36°C) on arrival to the intensive care unit (ICU) in one observational study [<a href="#rid117">117</a>]. Compared with normothermic patients, a propensity-matched cohort of these hypothermic patients had no differences in postoperative complications (eg, requirement for transfusion of blood products, prolonged duration of controlled ventilation, respiratory complications, gastrointestinal complications, sternal wound infection, sepsis, death).</p><p class="headingAnchor" id="H116644631"><span class="h1">INABILITY TO CLOSE THE STERNUM</span><span class="headingEndMark"> — </span>Once hemostasis has been achieved in a patient with hemodynamic and general stability, the sternal retractor is removed, and sternal wires are placed to close the chest. Although sternal closure may cause a slight decrease in the cardiac index (CI) and a slight increase in central venous pressure and/or pulmonary artery pressure owing to compression of the right atrium and ventricle, the surgeon can proceed to close the chest if hemodynamic stability is maintained.</p><p>In some patients, particularly those undergoing complex cardiac operations requiring a prolonged duration of CPB, attempted chest closure causes severe hypotension that mandates leaving the sternum open. In these cases, compression of the right atrium and ventricle impairs ventricular filling and decreases CI; these effects are exaggerated in a hypovolemic patient [<a href="#rid118">118</a>]. Attempts to close the sternum may also compromise the surgical repair (eg, kinking of a graft or trapping of a graft in the sternal wall) or cause pacing wire displacement, with resultant hemodynamic instability. Rarely, sternal closure results in entrapment of lung parenchyma or restriction of lung expansion that manifests as increased airway pressure.</p><p>If necessary, delayed sternal closure can be performed on a subsequent postoperative day; this is necessary in approximately 4 percent of cardiac surgical cases [<a href="#rid119">119</a>]. Delayed sternal closure eliminates compression of the heart by the sternum, reduces the likelihood of tamponade, and facilitates mediastinal re-exploration if necessary. However, the sternum remains unstable and risk of intrathoracic infection is increased. (See  <a class="medical medical_review" href="/z/d/html/15123.html" rel="external">"Surgical management of sternal wound complications"</a>.)</p><p>The most common indications for delayed sternal closure are low cardiac output syndrome, diffuse bleeding, arrhythmias, tamponade, or cardiac edema. Mortality is higher in patients undergoing delayed sternal closure if ejection fraction is low (&lt;30 percent) with prolonged duration of inotrope requirement, closure is delayed more than six days, or a sternal wound infection develops.</p><p class="headingAnchor" id="H3993351206"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118172.html" rel="external">"Society guideline links: Management of cardiopulmonary bypass"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H896401852"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular problems </strong>–<strong> </strong>Cardiovascular problems that may result in hypotension immediately after cardiopulmonary bypass (CPB) include left ventricular (LV) dysfunction, right ventricular (RV) dysfunction, vasoplegia, arrhythmias, air embolization, LV outflow tract (LVOT) obstruction, and other surgical technical problems. (See <a class="local">'Cardiovascular problems'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest not routinely administering inotropic and vasopressor drugs (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, vasoactive drugs may be necessary to treat low cardiac output syndrome or vasoplegia in the postbypass period. (See <a class="local">'Vasoactive drug therapy'</a> above and <a class="local">'Controversies regarding use of inotropic drug therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In selected patients with postcardiotomy cardiogenic shock, temporary mechanical circulatory support (eg, intraaortic balloon pump [IABP] counterpulsation, percutaneous or implantable ventricular assist device (VAD), extracorporeal membrane oxygenation [ECMO]) may be necessary. Device selection depends on individual patient hemodynamic factors, surgical preferences, and institutional resources. (See <a class="local">'Cardiogenic shock'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary problems</strong> – Airway obstruction, bronchospasm, and pulmonary edema may occur in the immediate post-bypass period. We suggest a lung-protective ventilation strategy in the postbypass period (with low tidal volume [TV] &lt;8 mL/kg ideal body weight, positive end-expiratory pressure [PEEP] ≥5 cmH<sub>2</sub>O, and low driving pressure [peak inspiratory pressure – PEEP] &lt;16 cmH<sub>2</sub>O) to potentially reduce the incidence of postoperative pulmonary complications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These ventilator settings are consistent with recommendations for lung-protective ventilation for all patients undergoing anesthesia and surgery with use of mechanical ventilation. (See <a class="local">'Pulmonary problems'</a> above and  <a class="medical medical_review" href="/z/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults", section on 'Lung protective ventilation during anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding and coagulopathy</strong> – Management of bleeding and coagulopathy after CPB is addressed separately. (See  <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Achieving hemostasis and management of bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic disturbances</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrolyte abnormalities</strong> – Hypocalcemia, hypokalemia, hyperkalemia, or hypomagnesemia are common and may be associated with arrythmias and hemodynamic instability. (See <a class="local">'Metabolic abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperglycemia</strong> – We suggest maintaining the blood glucose level at &lt;180 mg/dL (10 mmol/L) during CPB and the postbypass period (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment is with intermittent doses of insulin if effective, or a continuous insulin drip if glucose levels are persistently elevated. We also recommend avoiding a more stringent target (eg, 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Hyperglycemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothermia</strong> – Hypothermia is associated with arrhythmias, increased bleeding, and delayed extubation. We employ measures to prevent and treat postbypass hypothermia including adequate rewarming prior to separation from CPB, increasing the room temperature, warming cold blood products and intravenous (IV) fluids, and use of patient warming devices that employ forced air or circulating fluid. (See <a class="local">'Hypothermia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inability to close the sternum</strong> – Occasionally, attempted chest closure causes severe hypotension. Causes include compression of the right atrium and RV that impairs ventricular filling or compromise of the surgical repair (eg, kinking of a graft or trapping of a graft in the sternal wall). In such patients, delayed sternal closure can be performed on a subsequent postoperative day. (See <a class="local">'Inability to close the sternum'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cui WW, Ramsay JG. Pharmacologic approaches to weaning from cardiopulmonary bypass and extracorporeal membrane oxygenation. Best Pract Res Clin Anaesthesiol 2015; 29:257.</a></li><li><a class="nounderline abstract_t">Bouchard-Dechêne V, Couture P, Su A, et al. Risk Factors for Radial-to-Femoral Artery Pressure Gradient in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2018; 32:692.</a></li><li><a class="nounderline abstract_t">Licker M, Diaper J, Cartier V, et al. Clinical review: management of weaning from cardiopulmonary bypass after cardiac surgery. Ann Card Anaesth 2012; 15:206.</a></li><li><a class="nounderline abstract_t">Mebazaa A, Pitsis AA, Rudiger A, et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010; 14:201.</a></li><li><a class="nounderline abstract_t">Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review. Crit Care 2005; 9:266.</a></li><li><a class="nounderline abstract_t">Parissis JT, Rafouli-Stergiou P, Stasinos V, et al. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care 2010; 16:432.</a></li><li><a class="nounderline abstract_t">Nielsen DV, Johnsen SP, Madsen M, Jakobsen CJ. Variation in use of peroperative inotropic support therapy in cardiac surgery: time for reflection? Acta Anaesthesiol Scand 2011; 55:352.</a></li><li><a class="nounderline abstract_t">Hernandez AF, Li S, Dokholyan RS, et al. Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons. Am Heart J 2009; 158:47.</a></li><li><a class="nounderline abstract_t">Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002; 73:325.</a></li><li><a class="nounderline abstract_t">Yamada T, Takeda J, Katori N, et al. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth 2000; 14:367.</a></li><li><a class="nounderline abstract_t">Pirracchio R, Parenica J, Resche Rigon M, et al. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 2013; 8:e71659.</a></li><li><a class="nounderline abstract_t">Rong LQ, Rahouma M, Abouarab A, et al. Intravenous and Inhaled Milrinone in Adult Cardiac Surgery Patients: A Pairwise and Network Meta-Analysis. J Cardiothorac Vasc Anesth 2019; 33:663.</a></li><li><a class="nounderline abstract_t">Nielsen DV, Hansen MK, Johnsen SP, et al. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology 2014; 120:1098.</a></li><li><a class="nounderline abstract_t">Vakamudi M. Weaning from cardiopulmonary bypass: problems and remedies. Ann Card Anaesth 2004; 7:178.</a></li><li><a class="nounderline abstract_t">Williams JB, Hernandez AF, Li S, et al. Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study. J Card Surg 2011; 26:572.</a></li><li><a class="nounderline abstract_t">Allen LA, Fonarow GC, Grau-Sepulveda MV, et al. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. Circ Heart Fail 2014; 7:251.</a></li><li><a class="nounderline abstract_t">Unverzagt S, Wachsmuth L, Hirsch K, et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2014; :CD009669.</a></li><li><a class="nounderline abstract_t">Faisal SA, Apatov DA, Ramakrishna H, Weiner MM. Levosimendan in Cardiac Surgery: Evaluating the Evidence. J Cardiothorac Vasc Anesth 2019; 33:1146.</a></li><li><a class="nounderline abstract_t">Harrison RW, Hasselblad V, Mehta RH, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013; 27:1224.</a></li><li><a class="nounderline abstract_t">Ng KT, Chan XL, Tan W, Wang CY. Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. J Clin Anesth 2019; 52:37.</a></li><li><a class="nounderline abstract_t">Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.</a></li><li><a class="nounderline abstract_t">Møller MH, Granholm A, Junttila E, et al. Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 2018; 62:420.</a></li><li><a class="nounderline abstract_t">Shahin J, DeVarennes B, Tse CW, et al. The relationship between inotrope exposure, six-hour postoperative physiological variables, hospital mortality and renal dysfunction in patients undergoing cardiac surgery. Crit Care 2011; 15:R162.</a></li><li><a class="nounderline abstract_t">Fellahi JL, Parienti JJ, Hanouz JL, et al. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008; 108:979.</a></li><li><a class="nounderline abstract_t">Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014; 63:2069.</a></li><li><a class="nounderline abstract_t">Bernard F, Denault A, Babin D, et al. Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass. Anesth Analg 2001; 92:291.</a></li><li><a class="nounderline abstract_t">Roshanali F, Yousefnia MA, Mandegar MH, et al. Decreased right ventricular function after coronary artery bypass grafting. Tex Heart Inst J 2008; 35:250.</a></li><li><a class="nounderline abstract_t">Raymond M, Grønlykke L, Couture EJ, et al. Perioperative Right Ventricular Pressure Monitoring in Cardiac Surgery. J Cardiothorac Vasc Anesth 2019; 33:1090.</a></li><li><a class="nounderline abstract_t">Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016; 18:226.</a></li><li><a class="nounderline abstract_t">Poidinger B, Kotzinger O, Rützler K, et al. Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:328.</a></li><li><a class="nounderline abstract_t">Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy 2010; 30:728.</a></li><li><a class="nounderline abstract_t">Gebhard CE, Rochon A, Cogan J, et al. Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration. J Cardiothorac Vasc Anesth 2019; 33:651.</a></li><li><a class="nounderline abstract_t">Sardo S, Osawa EA, Finco G, et al. Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth 2018; 32:2512.</a></li><li><a class="nounderline abstract_t">Elmi-Sarabi M, Deschamps A, Delisle S, et al. Aerosolized Vasodilators for the Treatment of Pulmonary Hypertension in Cardiac Surgical Patients: A Systematic Review and Meta-analysis. Anesth Analg 2017; 125:393.</a></li><li><a class="nounderline abstract_t">Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 2010; 22:140.</a></li><li><a class="nounderline abstract_t">Mekontso-Dessap A, Houël R, Soustelle C, et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001; 71:1428.</a></li><li><a class="nounderline abstract_t">Shaefi S, Mittel A, Klick J, et al. Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy. J Cardiothorac Vasc Anesth 2018; 32:1013.</a></li><li><a class="nounderline abstract_t">Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci 2015; 349:80.</a></li><li><a class="nounderline abstract_t">Abou-Arab O, Martineau L, Bar S, et al. Postoperative Vasoplegic Syndrome Is Associated With Impaired Endothelial Vasomotor Response in Cardiac Surgery: A Prospective, Observational Study. J Cardiothorac Vasc Anesth 2018; 32:2218.</a></li><li><a class="nounderline abstract_t">Denault AY, Tardif JC, Mazer CD, et al. Difficult and complex separation from cardiopulmonary bypass in high-risk cardiac surgical patients: a multicenter study. J Cardiothorac Vasc Anesth 2012; 26:608.</a></li><li><a class="nounderline abstract_t">Tsiouris A, Wilson L, Haddadin AS, et al. Risk assessment and outcomes of vasoplegia after cardiac surgery. Gen Thorac Cardiovasc Surg 2017; 65:557.</a></li><li><a class="nounderline abstract_t">Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology 2017; 126:85.</a></li><li><a class="nounderline abstract_t">Osawa EA, Rhodes A, Landoni G, et al. Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review. Crit Care Med 2016; 44:724.</a></li><li><a class="nounderline abstract_t">Jentzer JC, Vallabhajosyula S, Khanna AK, et al. Management of Refractory Vasodilatory Shock. Chest 2018; 154:416.</a></li><li><a class="nounderline abstract_t">Dünser MW, Bouvet O, Knotzer H, et al. Vasopressin in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth 2018; 32:2225.</a></li><li><a class="nounderline abstract_t">McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA 2018; 319:1889.</a></li><li><a class="nounderline abstract_t">Shanmugam G. Vasoplegic syndrome--the role of methylene blue. Eur J Cardiothorac Surg 2005; 28:705.</a></li><li><a class="nounderline abstract_t">Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588.</a></li><li><a class="nounderline abstract_t">McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: methylene blue to the rescue! Curr Opin Anaesthesiol 2018; 31:43.</a></li><li><a class="nounderline abstract_t">Wieruszewski PM, Nei SD, Maltais S, et al.. Vitamin C for vasoplegia after cardiopulmonary bypass: A case series. A&amp;A Practice 2018; 11:96.</a></li><li><a class="nounderline abstract_t">Bussard RL, Busse LW. Angiotensin II: a new therapeutic option for vasodilatory shock. Ther Clin Risk Manag 2018; 14:1287.</a></li><li><a class="nounderline abstract_t">Wakefield BJ, Sacha GL, Khanna AK. Vasodilatory shock in the ICU and the role of angiotensin II. Curr Opin Crit Care 2018; 24:277.</a></li><li><a class="nounderline abstract_t">Ortoleva JP, Cobey FC. A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy. J Cardiothorac Vasc Anesth 2019; 33:1310.</a></li><li><a class="nounderline abstract_t">Feih JT, Rinka JRG, Zundel MT. Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: ARetrospective Cohort Study. J Cardiothorac Vasc Anesth 2019; 33:1301.</a></li><li><a class="nounderline abstract_t">Shapeton AD, Mahmood F, Ortoleva JP. Hydroxocobalamin for the Treatment of Vasoplegia: A Review of Current Literature and Considerations for Use. J Cardiothorac Vasc Anesth 2019; 33:894.</a></li><li><a class="nounderline abstract_t">Bissell BD, Browder K, McKenzie M, Flannery AH. A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock. Ann Pharmacother 2018; 52:920.</a></li><li><a class="nounderline abstract_t">Antonucci E, Gleeson PJ, Annoni F, et al. Angiotensin II in Refractory Septic Shock. Shock 2017; 47:560.</a></li><li><a class="nounderline abstract_t">Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017; 377:419.</a></li><li><a class="nounderline abstract_t">Busse LW, Wang XS, Chalikonda DM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med 2017; 45:1285.</a></li><li><a class="nounderline abstract_t">Armour S, Armour TK, Joppa WR, et al. Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series. Anesth Analg 2019; 129:e1.</a></li><li><a class="nounderline abstract_t">Hessel EA 2nd. What's New in Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:2296.</a></li><li><a class="nounderline abstract_t">Klijian A, Khanna AK, Reddy VS, et al. Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. J Cardiothorac Vasc Anesth 2021; 35:51.</a></li><li><a class="nounderline abstract_t">Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med 2016; 374:1911.</a></li><li><a class="nounderline abstract_t">Rho RW. The management of atrial fibrillation after cardiac surgery. Heart 2009; 95:422.</a></li><li><a class="nounderline abstract_t">Wang DY, Richmond ME, Quinn TA, et al. Optimized temporary biventricular pacing acutely improves intraoperative cardiac output after weaning from cardiopulmonary bypass: a substudy of a randomized clinical trial. J Thorac Cardiovasc Surg 2011; 141:1002.</a></li><li><a class="nounderline abstract_t">Gottesman RF, McKhann GM, Hogue CW. Neurological complications of cardiac surgery. Semin Neurol 2008; 28:703.</a></li><li><a class="nounderline abstract_t">Fleck T, Ehrlich M, Czerny M, et al. Intraoperative iatrogenic type A aortic dissection and perioperative outcome. Interact Cardiovasc Thorac Surg 2006; 5:11.</a></li><li><a class="nounderline abstract_t">Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124:40.</a></li><li><a class="nounderline abstract_t">Lomivorotov VV, Efremov SM, Kirov MY, et al. Low-Cardiac-Output Syndrome After Cardiac Surgery. J Cardiothorac Vasc Anesth 2017; 31:291.</a></li><li><a class="nounderline abstract_t">Sylvin EA, Stern DR, Goldstein DJ. Mechanical support for postcardiotomy cardiogenic shock: has progress been made? J Card Surg 2010; 25:442.</a></li><li><a class="nounderline abstract_t">Cohen M, Urban P, Christenson JT, et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Eur Heart J 2003; 24:1763.</a></li><li><a class="nounderline abstract_t">Cheung AT, Savino JS, Weiss SJ. Beat-to-beat augmentation of left ventricular function by intraaortic counterpulsation. Anesthesiology 1996; 84:545.</a></li><li><a class="nounderline abstract_t">Kimura A, Toyota E, Lu S, et al. Effects of intraaortic balloon pumping on septal arterial blood flow velocity waveform during severe left main coronary artery stenosis. J Am Coll Cardiol 1996; 27:810.</a></li><li><a class="nounderline abstract_t">Lewis PA, Mullany DV, Townsend S, et al. Trends in intra-aortic balloon counterpulsation: comparison of a 669 record Australian dataset with the multinational Benchmark Counterpulsation Outcomes Registry. Anaesth Intensive Care 2007; 35:13.</a></li><li><a class="nounderline abstract_t">Hausmann H, Potapov EV, Koster A, et al. Prognosis after the implantation of an intra-aortic balloon pump in cardiac surgery calculated with a new score. Circulation 2002; 106:I203.</a></li><li><a class="nounderline abstract_t">Parissis H, Leotsinidis M, Akbar MT, et al. The need for intra aortic balloon pump support following open heart surgery: risk analysis and outcome. J Cardiothorac Surg 2010; 5:20.</a></li><li><a class="nounderline abstract_t">Tokmakoğlu H, Farsak B, Günaydin S, et al. Effectiveness of intraaortic balloon pumping in patients who were not able to be weaned from cardiopulmonary bypass after coronary artery bypass surgery and mortality predictors in the perioperative and early postoperative period. Anadolu Kardiyol Derg 2003; 3:124.</a></li><li><a class="nounderline abstract_t">Pulido JN, Park SJ, Rihal CS. Percutaneous left ventricular assist devices: clinical uses, future applications, and anesthetic considerations. J Cardiothorac Vasc Anesth 2010; 24:478.</a></li><li><a class="nounderline abstract_t">Marelli D, Shemin RJ. Post-cardiac surgery mechanical support: a tool for decision making. Circulation 2007; 116:586.</a></li><li><a class="nounderline abstract_t">Hernandez AF, Grab JD, Gammie JS, et al. A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. Circulation 2007; 116:606.</a></li><li><a class="nounderline abstract_t">Rossiter-Thornton M, Arun V, Forrest AP, et al. Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery. Heart Lung Circ 2008; 17:243.</a></li><li><a class="nounderline abstract_t">Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg 2013; 145:548.</a></li><li><a class="nounderline abstract_t">Fierro MA, Daneshmand MA, Bartz RR. Perioperative Management of the Adult Patient on Venovenous Extracorporeal Membrane Oxygenation Requiring Noncardiac Surgery. Anesthesiology 2018; 128:181.</a></li><li><a class="nounderline abstract_t">Mazzeffi MA, Rao VK, Dodd-O J, et al. Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists-Part I, Technical Aspects of Extracorporeal Membrane Oxygenation. Anesth Analg 2021; 133:1459.</a></li><li><a class="nounderline abstract_t">Sidebotham D, McGeorge A, McGuinness S, et al. Extracorporeal membrane oxygenation for treating severe cardiac and respiratory failure in adults: part 2-technical considerations. J Cardiothorac Vasc Anesth 2010; 24:164.</a></li><li><a class="nounderline abstract_t">Biancari F, Perrotti A, Dalén M, et al. Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients. J Cardiothorac Vasc Anesth 2018; 32:1175.</a></li><li><a class="nounderline abstract_t">Wang L, Wang H, Hou X. Clinical Outcomes of Adult Patients Who Receive Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock: A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth 2018; 32:2087.</a></li><li><a class="nounderline abstract_t">Karhunen JP, Sihvo EI, Suojaranta-Ylinen RT, et al. Predictive factors of hemodynamic collapse after coronary artery bypass grafting: a case-control study. J Cardiothorac Vasc Anesth 2006; 20:143.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Task Force on Resuscitation After Cardiac Surgery. The Society of Thoracic Surgeons Expert Consensus for the Resuscitation of Patients Who Arrest After Cardiac Surgery. Ann Thorac Surg 2017; 103:1005.</a></li><li><a class="nounderline abstract_t">Anthi A, Tzelepis GE, Alivizatos P, et al. Unexpected cardiac arrest after cardiac surgery: incidence, predisposing causes, and outcome of open chest cardiopulmonary resuscitation. Chest 1998; 113:15.</a></li><li><a class="nounderline abstract_t">Ecoff SA, Miyahara C, Steward DJ. Severe bronchospasm during cardiopulmonary bypass. Can J Anaesth 1996; 43:1244.</a></li><li><a class="nounderline abstract_t">Westhorpe RN, Ludbrook GL, Helps SC. Crisis management during anaesthesia: bronchospasm. Qual Saf Health Care 2005; 14:e7.</a></li><li><a class="nounderline abstract_t">Apostolakis E, Filos KS, Koletsis E, Dougenis D. Lung dysfunction following cardiopulmonary bypass. J Card Surg 2010; 25:47.</a></li><li><a class="nounderline abstract_t">Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.</a></li><li><a class="nounderline abstract_t">Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018; 32:88.</a></li><li><a class="nounderline abstract_t">Opie L. Myocardial stunning: a role for calcium antagonists during reperfusion? Cardiovasc Res 1992; 26:20.</a></li><li><a class="nounderline abstract_t">DiNardo JA. Pro: calcium is routinely indicated during separation from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:905.</a></li><li><a class="nounderline abstract_t">DeHert SG, Ten Broecke PW, De Mulder PA, et al. Effects of calcium on left ventricular function early after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:864.</a></li><li><a class="nounderline abstract_t">Prielipp R, Butterworth J. Con: calcium is not routinely indicated during separation from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:908.</a></li><li><a class="nounderline abstract_t">Janelle GM, Urdaneta F, Martin TD, Lobato EB. Effects of calcium chloride on grafted internal mammary artery flow after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000; 14:4.</a></li><li><a class="nounderline abstract_t">England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268:2395.</a></li><li><a class="nounderline abstract_t">Booth JV, Phillips-Bute B, McCants CB, et al. Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery. Am Heart J 2003; 145:1108.</a></li><li><a class="nounderline abstract_t">Osawa EA, Cutuli SL, Cioccari L, et al. Continuous Magnesium Infusion to Prevent Atrial Fibrillation After Cardiac Surgery: A Sequential Matched Case-Controlled Pilot Study. J Cardiothorac Vasc Anesth 2020; 34:2940.</a></li><li><a class="nounderline abstract_t">Teragawa H, Matsuura H, Chayama K, Oshima T. Mechanisms responsible for vasodilation upon magnesium infusion in vivo: clinical evidence. Magnes Res 2002; 15:241.</a></li><li><a class="nounderline abstract_t">Lazar HL, McDonnell M, Chipkin SR, et al. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg 2009; 87:663.</a></li><li><a class="nounderline abstract_t">Lazar HL. How important is glycemic control during coronary artery bypass? Adv Surg 2012; 46:219.</a></li><li><a class="nounderline abstract_t">NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.</a></li><li><a class="nounderline abstract_t">Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007; 146:233.</a></li><li><a class="nounderline abstract_t">Burchardi H, Kaczmarczyk G. The effect of anaesthesia on renal function. Eur J Anaesthesiol 1994; 11:163.</a></li><li><a class="nounderline abstract_t">Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29:1526.</a></li><li><a class="nounderline abstract_t">Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510.</a></li><li><a class="nounderline abstract_t">Tindall MJ, Peletier MA, Severens NM, et al. Understanding post-operative temperature drop in cardiac surgery: a mathematical model. Math Med Biol 2008; 25:323.</a></li><li><a class="nounderline abstract_t">John M, Ford J, Harper M. Peri-operative warming devices: performance and clinical application. Anaesthesia 2014; 69:623.</a></li><li><a class="nounderline abstract_t">Sessler DI. Complications and treatment of mild hypothermia. Anesthesiology 2001; 95:531.</a></li><li><a class="nounderline abstract_t">Yu PJ, Cassiere HA, Kohn N, et al. Impact of Postoperative Hypothermia on Outcomes in Coronary Artery Bypass Surgery Patients. J Cardiothorac Vasc Anesth 2017; 31:1257.</a></li><li><a class="nounderline abstract_t">Adsumelli RS, Shapiro JR, Shah PM, et al. Hemodynamic effects of chest closure in adult patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2001; 15:589.</a></li><li><a class="nounderline abstract_t">Boeken U, Feindt P, Schurr P, et al. Delayed sternal closure (DSC) after cardiac surgery: outcome and prognostic markers. J Card Surg 2011; 26:22.</a></li></ol></div><div id="topicVersionRevision">Topic 115472 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060034" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacologic approaches to weaning from cardiopulmonary bypass and extracorporeal membrane oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217231" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk Factors for Radial-to-Femoral Artery Pressure Gradient in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772515" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical review: management of weaning from cardiopulmonary bypass after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20497611" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987381" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20711077" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Inotropes in cardiac patients: update 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288219" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Variation in use of peroperative inotropic support therapy in cardiac surgery: time for reflection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540391" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834047" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intravenous milrinone in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972598" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977106" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287183" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intravenous and Inhaled Milrinone in Adult Cardiac Surgery Patients: A Pairwise and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614322" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17827556" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Weaning from cardiopulmonary bypass: problems and remedies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951076" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488983" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385385" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30055988" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Levosimendan in Cardiac Surgery: Evaluating the Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050857" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30172838" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28316276" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28320259" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Levosimendan for Hemodynamic Support after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479665" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21736726" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The relationship between inotrope exposure, six-hour postoperative physiological variables, hospital mortality and renal dysfunction in patients undergoing cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18497597" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24530672" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inotropes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159219" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941594" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Decreased right ventricular function after coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30269893" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Perioperative Right Ventricular Pressure Monitoring in Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26995592" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30122612" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20575636" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30683595" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703580" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598920" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aerosolized Vasodilators for the Treatment of Pulmonary Hypertension in Cardiac Surgical Patients: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21092891" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vasoplegia during cardiac surgery: current concepts and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11383777" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29223724" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247756" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29548905" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Postoperative Vasoplegic Syndrome Is Associated With Impaired Endothelial Vasomotor Response in Cardiac Surgery: A Prospective, Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578975" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Difficult and complex separation from cardiopulmonary bypass in high-risk cardiac surgical patients: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28612323" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk assessment and outcomes of vasoplegia after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27841822" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646462" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29329694" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Management of Refractory Vasodilatory Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29748077" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vasopressin in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29801010" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143539" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vasoplegic syndrome--the role of methylene blue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529214" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The pathogenesis of vasodilatory shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29176374" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intraoperative vasoplegia: methylene blue to the rescue!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vitamin C for vasoplegia after cardiopulmonary bypass: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30100727" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Angiotensin II: a new therapeutic option for vasodilatory shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29877879" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vasodilatory shock in the ICU and the role of angiotensin II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30598380" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606508" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: ARetrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30217583" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hydroxocobalamin for the Treatment of Vasoplegia: A Review of Current Literature and Considerations for Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29582666" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879559" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Angiotensin II in Refractory Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528561" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Angiotensin II for the Treatment of Vasodilatory Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489648" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29979199" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928282" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : What's New in Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32868152" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043047" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218267" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The management of atrial fibrillation after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800242" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Optimized temporary biventricular pacing acutely improves intraoperative cardiac output after weaning from cardiopulmonary bypass: a substudy of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115176" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Neurological complications of cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17670501" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intraoperative iatrogenic type A aortic dissection and perioperative outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670234" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671216" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Low-Cardiac-Output Syndrome After Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20487107" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mechanical support for postcardiotomy cardiogenic shock: has progress been made?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522572" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659782" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Beat-to-beat augmentation of left ventricular function by intraaortic counterpulsation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613607" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of intraaortic balloon pumping on septal arterial blood flow velocity waveform during severe left main coronary artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17323660" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Trends in intra-aortic balloon counterpulsation: comparison of a 669 record Australian dataset with the multinational Benchmark Counterpulsation Outcomes Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354734" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prognosis after the implantation of an intra-aortic balloon pump in cardiac surgery calculated with a new score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367880" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The need for intra aortic balloon pump support following open heart surgery: risk analysis and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12826506" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effectiveness of intraaortic balloon pumping in patients who were not able to be weaned from cardiopulmonary bypass after coronary artery bypass surgery and mortality predictors in the perioperative and early postoperative period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056444" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Percutaneous left ventricular assist devices: clinical uses, future applications, and anesthetic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679625" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Post-cardiac surgery mechanical support: a tool for decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646586" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436482" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405676" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28984630" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Perioperative Management of the Adult Patient on Venovenous Extracorporeal Membrane Oxygenation Requiring Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34559089" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intraoperative Management of Adult Patients on Extracorporeal Membrane Oxygenation: An Expert Consensus Statement From the Society of Cardiovascular Anesthesiologists-Part I, Technical Aspects of Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875307" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Extracorporeal membrane oxygenation for treating severe cardiac and respiratory failure in adults: part 2-technical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29158060" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678433" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical Outcomes of Adult Patients Who Receive Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616651" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Predictive factors of hemodynamic collapse after coronary artery bypass grafting: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122680" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The Society of Thoracic Surgeons Expert Consensus for the Resuscitation of Patients Who Arrest After Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440561" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Unexpected cardiac arrest after cardiac surgery: incidence, predisposing causes, and outcome of open chest cardiopulmonary resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955975" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Severe bronchospasm during cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933304" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Crisis management during anaesthesia: bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549041" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lung dysfunction following cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029990" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516108" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Myocardial stunning: a role for calcium antagonists during reperfusion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412896" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pro: calcium is routinely indicated during separation from cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412886" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effects of calcium on left ventricular function early after cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412897" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Con: calcium is not routinely indicated during separation from cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10698383" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effects of calcium chloride on grafted internal mammary artery flow after cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404796" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796771" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32493662" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Continuous Magnesium Infusion to Prevent Atrial Fibrillation After Cardiac Surgery: A Sequential Matched Case-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635879" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Mechanisms responsible for vasodilation upon magnesium infusion in vivo: clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19161815" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873042" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : How important is glycemic control during coronary artery bypass?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318384" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Intensive versus conventional glucose control in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310047" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050420" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The effect of anaesthesia on renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11505120" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Use of dopamine in acute renal failure: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809463" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990682" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Understanding post-operative temperature drop in cardiac surgery: a mathematical model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24720346" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Peri-operative warming devices: performance and clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11506130" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Complications and treatment of mild hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506458" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Impact of Postoperative Hypothermia on Outcomes in Coronary Artery Bypass Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688000" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Hemodynamic effects of chest closure in adult patients undergoing cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21073533" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Delayed sternal closure (DSC) after cardiac surgery: outcome and prognostic markers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
